Investment Summary |
|
|---|---|
| Date | 2024-04-16 |
| Target | Curida |
| Sector | Life Science |
| Investor(s) | Signet Healthcare Partners |
| Deal Type | Growth Capital |
| Advisor(s) | DNB Markets (Financial) Simonsen Vogt Wiig (Legal) |
SEARCH BY
Try For Free 7-Day Free Trial
| Category | Growth Capital Firm |
|---|---|
| Founded | 1998 |
| PE ASSETS | 500M USD |
| Size | Middle-Market |
| Type | Sector Focused |
Signet Healthcare Partners is a growth capital firm focused on the healthcare sector. Specific areas of interest include speciality pharmaceuticals, pharmaceutical services, medical devices, and diagnostics. Signet will consider opportunities throughout North America and Europe and looks to commit $10 to $50 million per transaction. Signet Healthcare Partners was established in 1998 and is headquartered in New York City.
| DEAL STATS | # |
|---|---|
| Overall | 14 of 14 |
| Sector (Life Science) | 12 of 12 |
| Type (Growth Capital) | 9 of 9 |
| Country (Norway) | 1 of 1 |
| Year (2024) | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2022-10-24 |
Laxai
Hyderabad, India Laxai offers contract research, development, and manufacturing solutions to pharmaceutical and specialty chemical companies globally. Laxai has collaborated with pharmaceutical companies across the value chain and partnered on multiple medicinal chemistry, integrated drug discovery, CMC Programs, and scale-up of custom-made specialty fine chemicals. Laxai is based in Hyderabad, India. |
Buy | - |
